Description of SS-31

SS-31, also known as the Szeto-Schiller (SS) peptide, is an innovative synthetic tetrapeptide developed around the year 2000 by scientists Hazel H. Szeto and Peter W. Schiller. Initially designed as a ligand for the μ-opioid receptor, it unexpectedly demonstrated a remarkable ability to selectively accumulate in mitochondria, where it interacts with the phospholipid cardiolipin in the inner mitochondrial membrane. This interaction stabilizes mitochondrial structure, enhances efficient ATP production, and concurrently reduces the formation of reactive oxygen species (ROS), which are key contributors to cellular damage and aging. Due to its small molecular size and lipophilic properties, SS-31 readily crosses cellular and organelle membranes, allowing it to efficiently target mitochondria across diverse tissue types.

Mitochondrial dysfunction, often linked to the degradation or destabilization of cardiolipin, underlies a wide range of chronic and degenerative diseases, including neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s diseases), metabolic syndromes, cancer, cardiomyopathies, and mitochondrial myopathies. SS-31 is currently undergoing clinical trials as a therapeutic agent for heart failure, primary mitochondrial myopathy, and other mitochondrial disorders. Recent research using chemical cross-linking and mass spectrometry has revealed that SS-31 interacts with multiple key mitochondrial proteins involved in oxidative phosphorylation and 2-oxoglutarate metabolism, further supporting its potential as a targeted mitochondrial therapeutic..

[1]

Research Confirmed Effects

1. SS-31 and Mitochondrial Function Support

Primary mitochondrial diseases (PMDs) are a group of genetically determined disorders caused by dysfunction of the mitochondrial apparatus, which is responsible for the production of cellular energy in the form of ATP. These conditions primarily affect organ systems with high energy demands, such as skeletal muscle, the heart, nervous system, and kidneys. SS-31 (Elamipretide) is a mitochondria-targeted synthetic tetrapeptide that interacts with cardiolipin in the inner mitochondrial membrane, thereby stabilizing mitochondrial structure, reducing oxidative stress, and restoring ATP synthesis function. Initial preclinical evidence of SS-31’s efficacy emerged from animal studies involving ischemia-reperfusion injury, where treatment accelerated ATP recovery, reduced necrosis and apoptosis, and promoted tissue function restoration.

Important insights have also come from experiments investigating the effects of SS-31 on aging skeletal muscle. In older mice, a single dose of SS-31 led to a rapid improvement in mitochondrial bioenergetics, reflected by increased ATP production, improved phosphorylation efficiency (P/O ratio), and enhanced cellular energy status. These effects were not observed in younger animals, suggesting a specific action of the tetrapeptide on age-related mitochondrial deficits. Moreover, SS-31 reduced redox stress, mitochondrial H₂O₂ emission, and improved muscle fatigue resistance, resulting in increased physical endurance after 8 days of treatment. These findings support its therapeutic potential in combating sarcopenia and other forms of age-related mitochondrial dysfunction.

SS-31 has also demonstrated efficacy in preventing kidney injury resulting from ischemia-reperfusion (I/R) stress, where rapid reactivation of mitochondrial function during the early phase of reperfusion is critical for the survival of tubular cells. The peptide inhibits the opening of the mitochondrial permeability transition (MPT) pore, thereby preventing mitochondrial depolarization, reducing ROS production, and attenuating inflammation. These multifactorial effects highlight its therapeutic potential not only for genetically driven mitochondrial diseases but also for acute and age-related mitochondrial dysfunctions.

Ischemia induces acute kidney injury (AKI) primarily due to ATP depletion, and rapid ATP recovery upon reperfusion is essential to minimize tissue damage. This recovery process is often impaired by the destruction of mitochondrial cristae, which are essential for efficient ATP synthesis. SS-31 binds with high affinity to cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and preventing cardiolipin peroxidation through inhibition of cytochrome c peroxidase activity. The resulting effects include mitochondrial protection during ischemia, accelerated ATP restoration following reperfusion, recovery of the actin cytoskeleton and cell polarity, inhibition of apoptosis, and an overall reduction in renal dysfunction. These mechanisms affirm SS-31’s potential as a promising candidate for the treatment of ischemia-reperfusion injury, which is currently being evaluated in clinical trials.

Although phase III clinical trials with the peptide SS-31 did not yield conclusive results, earlier phase II studies demonstrated encouraging signs of improved physical performance in patients with primary mitochondrial myopathy (PMM) after only five days of treatment, without serious adverse effects. The peptide acts specifically on cardiolipin—an essential phospholipid of the mitochondrial membrane—stabilizing it and protecting it from oxidative damage, thereby potentially restoring mitochondrial function.

While the phase III study failed to meet its predefined primary endpoints (e.g., improvement in 6-minute walk distance and fatigue), the drug’s safety profile remains favorable. Researchers and experts, such as Dr. Bruce Cohen, have suggested that the selected endpoints may not have been appropriate and that further investigations may reveal the therapeutic potential of elamipretide not only for PMM but also for other mitochondrial diseases, including Barth syndrome and age-related macular degeneration.

Currently, SS-31 is considered one of the few promising candidates for the treatment of mitochondrial disorders. Ongoing research is being conducted through additional clinical trials involving new indications, extended durations, and alternative efficacy endpoints. In parallel, derivatives of SS-31 and other mitochondria-targeted molecules are also being investigated, fostering hope that significant advances in the treatment of mitochondrial dysfunctions may be achieved in the near future.

[2]–[8]

2. SS-31 and Cardiac Ischemia

Mitochondrial dysfunction represents a key pathological component in heart failure and ischemia-reperfusion injury of the myocardium. The peptide SS-31 has emerged as a promising therapeutic agent capable of selectively targeting mitochondrial function, primarily through its interaction with cardiolipin. Studies on human cardiac tissue have demonstrated that SS-31 can enhance mitochondrial oxygen flux and respiratory complex activity without requiring cardiolipin remodeling, suggesting the involvement of multiple mechanisms of action. These findings support the broader application of SS-31 in the treatment of mitochondrial dysfunction associated with cardiovascular diseases.

Animal model experiments, specifically in dogs with advanced heart failure, have confirmed the beneficial effects of chronic SS-31 treatment on improving left ventricular function and enhancing mitochondrial ATP production. This correlation suggests that SS-31 may contribute to the restoration of myocardial energy balance and slow down the process of cardiac tissue remodeling. Moreover, the peptide has also shown efficacy in acute settings, demonstrating the ability to reduce levels of HtrA2—a protease released from mitochondria during apoptosis, which is characteristic of ischemia-reperfusion injury.

Clinical and preclinical evidence indicates that SS-31 holds potential as a protective agent against both acute and chronic mitochondrial injury in cardiovascular diseases. In cases of ST-elevation myocardial infarction (STEMI), it has been shown to significantly reduce mitochondrial apoptosis, thereby preserving cardiomyocyte viability. These findings support the growing interest in mitochondria as a therapeutic target, with SS-31 emerging as one of the most promising candidates for clinical application in the prevention and treatment of myocardial ischemia.

[5], [9], [10]

3. SS-31 in Diabetes

Mitochondrial damage has emerged as a key factor in the pathogenesis of type 2 diabetes, with oxidative stress playing a central role in the development of complications such as microvascular disease. SS-31, a mitochondria-targeted peptide, has demonstrated efficacy in reducing the production of reactive oxygen species (ROS) associated with mitochondrial dysfunction in diabetes. Studies in both human and animal models have shown that SS-31 treatment reduces oxidative damage, improves mitochondrial membrane potential, and increases levels of SIRT1, which are associated with enhanced insulin sensitivity. These effects suggest that SS-31 may help slow or halt the progression of diabetic complications, including microvascular disease.

Further research indicates that SS-31 exerts beneficial effects in reducing oxidative stress and inflammation in patients with type 2 diabetes mellitus, potentially lowering the risk of cardiovascular disease—a common complication of this condition. Treatment with SS-31 was found to reduce levels of pro-inflammatory markers such as NFκB-p65 and TNFα, while also improving interactions between leukocytes and endothelial cells. These findings support the hypothesis that SS-31 may serve as an effective agent for enhancing mitochondrial function and alleviating inflammatory processes frequently associated with long-term diabetic complications, particularly in the context of cardiovascular health.

[11], [14]

4. SS-31 and Inflammation Suppression

SS-31 has emerged as a strong candidate in combating chronic inflammation, primarily through its impact on mitochondrial oxidative stress. This tetrapeptide demonstrates the ability to effectively scavenge reactive oxygen species (ROS), thereby preventing the initiation of intracellular inflammatory cascades. Studies conducted on cell cultures and animal models have confirmed that SS-31 inhibits inflammatory pathways by downregulating the expression of proteins such as CD36, FIS1, and NF-κB p65, which are known to act as key triggers of inflammation. For instance, the suppression of FIS1—a regulator of mitochondrial fission—helps maintain mitochondrial integrity and prevents activation of the inflammasome, a process frequently responsible for eliciting inflammatory responses. Additionally, SS-31 stabilizes mitochondrial morphology, exerting a protective effect particularly in neuroinflammatory conditions such as Alzheimer's disease or CNS injury during sepsis.

Another important property of SS-31 is its ability to suppress the activity of ROS-producing enzymes such as NADPH oxidase, while simultaneously enhancing the expression of antioxidant defense mechanisms, including MnSOD and catalase. These effects result in reduced levels of pro-inflammatory cytokines such as TNF-α and suppression of the transcription factor NF-κB, which plays a central role in chronic inflammation. Furthermore, treatment with SS-31 has been associated with decreased tissue damage and improved histological parameters, for example in the kidneys of diabetic mice, indicating its potential in the prevention and treatment of inflammatory complications in chronic diseases. These findings support the use of SS-31 as a therapeutic agent with broad-spectrum anti-inflammatory effects, grounded in mitochondrial protection and restoration of cellular homeostasis.

[12], [13]

References

1. Juan D. Chavez, Xiaoting Tang, Matthew D. Campbell, James E. Bruce, „Mitochondrial protein interaction landscape of SS-31“, 2020.
2. H. H. Szeto et al., “Mitochondria-Targeted Peptide Accelerates ATP Recovery and Reduces Ischemic Kidney Injury,” J. Am. Soc. Nephrol. JASN, vol. 22, no. 6, pp. 1041–1052, Jun. 2011, doi: 10.1681/ASN.2010080808.
3. M. P. Siegel et al., “Mitochondrial targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice,” Aging Cell, vol. 12, no. 5, pp. 763–771, Oct. 2013, doi: 10.1111/acel.12102.
4. A. V. Birk et al., “The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin,” J. Am. Soc. Nephrol. JASN, vol. 24, no. 8, pp. 1250–1261, Jul. 2013, doi: 10.1681/ASN.2012121216.
5. K. C. Chatfield et al., “Elamipretide Improves Mitochondrial Function in the Failing Human Heart,” JACC Basic Transl. Sci., vol. 4, no. 2, pp. 147–157, Apr. 2019, doi: 10.1016/j.jacbts.2018.12.005.
6. A. Karaa, R. Haas, A. Goldstein, J. Vockley, W. D. Weaver, and B. H. Cohen, “Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy,” Neurology, vol. 90, no. 14, pp. e1212–e1221, Apr. 2018, doi: 10.1212/WNL.0000000000005255.
7. A. M. PhD, “Elamipretide Failed to Meet Promise of Earlier Trial Results for...,” Mitochondrial Disease News, Jan. 10, 2020. https://mitochondrialdiseasenews.com/2020/01/10/elamipretide-failed-to-meet-promise-of-earlier-trial-results-for-primary-mitochondrial-myopathy-data-show/ (accessed Apr. 06, 2020).
8. “Could Elamipretide Become the First Treatment Option for Primary Mitochondrial Myopathy?,” Neurology Live. https://www.neurologylive.com/clinical-focus/could-elamipretide-treatment-option-primary-mitochondrial-myopathy (accessed Apr. 06, 2020).
9. H. N. Sabbah, R. C. Gupta, S. Kohli, M. Wang, S. Hachem, and K. Zhang, “Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure,” Circ. Heart Fail., vol. 9, no. 2, p. e002206, Feb. 2016, doi: 10.1161/CIRCHEARTFAILURE.115.002206.
10. M. Hortmann et al., “The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction,” Eur. Heart J. Acute Cardiovasc. Care, vol. 8, no. 8, pp. 695–702, Dec. 2019, doi: 10.1177/2048872617710789.
11. I. Escribano-Lopez et al., “The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes,” Sci. Rep., vol. 8, no. 1, pp. 1–10, Oct. 2018, doi: 10.1038/s41598-018-34251-8.
12. Y. Mo et al., “SS-31 reduces inflammation and oxidative stress through the inhibition of Fis1 expression in lipopolysaccharide-stimulated microglia,” Biochem. Biophys. Res. Commun., vol. 520, no. 1, pp. 171–178, Nov. 2019, doi: 10.1016/j.bbrc.2019.09.077.
13. Y. Hou et al., “The antioxidant peptide SS31 prevents oxidative stress, downregulates CD36 and improves renal function in diabetic nephropathy,” Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc., vol. 33, no. 11, pp. 1908–1918, 01 2018, doi: 10.1093/ndt/gfy021.
14. Y. Hou et al., “Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy,” Am. J. Physiol.-Ren. Physiol., vol. 310, no. 6, pp. F547–F559, Dec. 2015, doi: 10.1152/ajprenal.00574.2014.